Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).

Ivor John Percent,Craig H. Reynolds,Kartik Konduri,Matthew Thomas Whitehurst,Emmanuel A. Nidhiry,Ronald Yanagihara,Misako Nagasaka,Marshall T. Schreeder,James Uyeki,Georges Azzi,Krishna Kishore Pachipala,Jason C. Comer,Rachel E. Lerner,Ticiana Leal,Delia Alvarez,Saskia T. C. Neuteboom,Natasha Reddinger,Xiaohong Yan,Ronald L. Shazer,David M. Waterhouse

Phase III trial of sitravatinib plus nivolumab vs. docetaxel for treatment of NSCLC after platinum-based chemotherapy and immunotherapy (SAPPHIRE).

2020

TPS9635Background: Sitravatinib is an oral spectrum-selective tyrosine kinase inhibitor that targets the TAM (TYRO3/AXL/MERTK) and split (VEGFR2/KIT) family receptor tyrosine kinases (RTKs), as wel...

Keywords:

Docetaxel
Platinum
Immunotherapy
Nivolumab
Internal medicine
Oncology
Medicine
Pathology
Chemotherapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations